Lunai Bioworks corrects press release link regarding expanded lawsuit

WILMINGTON, Del., and SACRAMENTO, Calif., Lunai Bioworks, Inc. (NASDAQ: LNAI) has issued a correction to a press release issued on August 27, 2026, regarding the company's expanded naked short selling lawsuit. The sole change is to a reference link on the company's website, directing readers to a specific document on the Investor Relations section. No other content from the original press release has been altered.

The correction affects the hyperlink for the Second Amended Complaint, which was filed in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC). The revised link now points to the correct document, ensuring that investors and the public can easily access the full text of the complaint.

Lunai Bioworks, a biology-first drug discovery company, continues its efforts to decode the molecular underpinnings of central nervous system diseases. The company's Augusta AI platform uses real patient data to identify disease sub-populations, trace altered genes to candidate compounds, and validate drug candidates through CRISPR-induced zebrafish models and proprietary machine vision. Lunai's pipeline focuses on Alzheimer's disease, Parkinson's disease, epilepsy, and alcohol use disorder.

Additionally, the company operates an AI-powered biodefense program through its BioSymetrics platform. This program applies the company’s drug discovery platform in reverse to identify chemical threats and develop countermeasures. Lunai Bioworks was formed through the April 2025 merger of Renovaro Inc. and BioSymetrics, Inc. and is headquartered in California.

The company notes that its release contains forward-looking statements, including statements regarding pending litigation, which are subject to risks and uncertainties. Lunai undertakes no obligation to update these statements except as required by law.